SHINVA新华品牌怎么样 申请店铺

我要投票 SHINVA新华在医疗器械行业中的票数:399 更新时间:2025-06-29
SHINVA新华是哪个国家的品牌?「SHINVA新华」是 山东新华医疗器械股份有限公司 旗下著名品牌。该品牌发源于山东,由创始人许尚峰在1993期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力SHINVA新华品牌出海!将品牌入驻外推网,定制SHINVA新华品牌推广信息,可以显著提高SHINVA新华产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

SHINVA新华怎么样

2002年9月,山东新华医疗器械股份有限公司在上海证券交易所上市,现为中国医疗器械行业协会会长单位。

山东新华医疗器械股份有限公司始终坚持拼搏诚信的齐鲁文化、以用户为中心的现代企业文化为企业核心价值观,用目标鼓舞士气,用发展凝聚人心,用创新提升素质,用文化打造实力,坚定不移地走健康产业之路,坚定不移地走技术创新之路,坚定不移地走资本运作之路,拥有医疗器械及装备、制药装备、医疗服务三大业务板块。

在医疗器械板块,已形成九大配置精良、技术完备的先进产品线,涵盖感染控制、放疗及影像、手术器械及骨科、手术室工程及设备、口腔设备及耗材、体外诊断试剂及仪器、生物材料及耗材、透析设备及耗材、医用环保及其他领域。

制药装备板块,由生物制药、特种输液、中药制剂、固体制剂四大工程技术中心组成,下设八个产品技术分厂和五个控股公司,集制药装备研发、制造及销售为一体。在常规制药装备生产之外,提供着“制药工艺、制药装备、制药工程”三位一体的优质服务;同时,为化学药、生物药、植物药工厂的建设提供整包服务,为客户解决一切后顾之忧。

在医疗服务领域,新华医疗持续提升着品牌竞争力和美誉度。凭借专业的投资、建设、运营及采购和服务平台,打造具有先进医疗理念、前沿科研水平、品牌经营连锁、资源有机融合的现代化医院集团。与此同时,新华医疗也在积极拓展着肾脏健康服务,利用公司专业化、集约化、连锁化的运营优势,为医院提供新技术、新管理、新模式,创建出一系列特色鲜明的肾脏病专科医院和血液透析中心,用无限的责任感和专业度,服务于广大肾病患者。未来,新华医疗,将以集团化、专业化、规范化的全新面貌,为更多患者提供完善医疗服务,成就发展健康产业之路的宏伟梦想。

公司以山东核心区域为研发、制造、营销和管理总部,同时有北京核心区域、上海核心区域。

心系健康,诚信天下。站在新的历史起点上,面对新的发展机遇,新华医疗将一如既往,与时俱进,以自信、创新和拼搏,去勇敢面对困难和挑战,为人类健康事业、为铸造中国医疗器械产业的丰碑、打造世界知名医疗器械生产企业而继续努力奋斗!

In September 2002, Shandong Xinhua medical device Co., Ltd. was listed on the Shanghai Stock Exchange and is now the chairman of China Medical Device Industry Association. Shandong Xinhua Medical Equipment Co., Ltd. always adheres to the Qilu culture of striving for integrity, the modern enterprise culture centered on users as the core values of the enterprise, encourages morale with goals, rallies people with development, improves quality with innovation, builds strength with culture, firmly takes the road of health industry, firmly takes the road of technological innovation, and firmly takes the road of capital The way of operation, with medical devices and equipment, pharmaceutical equipment, medical services three business sectors. In the medical equipment sector, nine advanced product lines with excellent configuration and complete technology have been formed, covering infection control, radiotherapy and imaging, surgical equipment and orthopedics, operating room engineering and equipment, oral equipment and consumables, in vitro diagnostic reagents and instruments, biomaterials and consumables, dialysis equipment and consumables, medical environmental protection and other fields. The pharmaceutical equipment sector is composed of four engineering technology centers, including biopharmaceutical, special infusion, traditional Chinese medicine preparation and solid preparation. It has eight product technology branches and five holding companies, integrating the R & D, manufacturing and sales of pharmaceutical equipment. In addition to the production of conventional pharmaceutical equipment, it provides the high-quality service of "pharmaceutical technology, pharmaceutical equipment, pharmaceutical engineering"; at the same time, it provides the whole package service for the construction of chemical medicine, biological medicine, plant medicine factories, and solves all the worries for customers. In the field of medical services, Xinhua medical continues to enhance its brand competitiveness and reputation. With professional investment, construction, operation, procurement and service platform, we will build a modern hospital group with advanced medical concept, cutting-edge scientific research level, brand management chain and organic integration of resources. At the same time, Xinhua medical is also actively expanding kidney health services, taking advantage of the company's professional, intensive and chain operation advantages to provide new technology, new management and new mode for the hospital, creating a series of distinctive kidney disease specialized hospitals and hemodialysis centers, serving the vast number of nephrotic patients with unlimited sense of responsibility and professionalism. In the future, Xinhua medical will take a new look of collectivization, specialization and standardization to provide more patients with perfect medical services and achieve the grand dream of developing health industry. The company takes the core area of Shandong Province as its R & D, manufacturing, marketing and management headquarters, and has the core areas of Beijing and Shanghai. Heart health, integrity world. Standing at a new historical starting point and facing new development opportunities, Xinhua medical will, as always, keep pace with the times, bravely face difficulties and challenges with self-confidence, innovation and hard work, and continue to strive for the cause of human health, the building of a monument of China's medical device industry and the building of a world-famous medical device manufacturer!

本文链接: https://brand.waitui.com/f0c49f885.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

成都先导:终止收购南京海纳医药科技约65%股权事项

成都先导公告,公司原拟以现金方式受让股权的方式合计取得南京海纳医药科技股份有限公司约65%的股权。《股权收购意向书》签署后,公司积极组织交易各方推进本次交易,聘请了专业的中介机构对标的公司展开尽调,在此基础上,交易各方对本次交易方案进行多次论证和协商,但未能就本次交易事项的核心条款达成一致意见。 为切实维护公司及全体股东利益,经公司充分审慎研究并与交易对方友好协商,交易各方一致同意终止本次交易事项,本次重大资产重组事项终止。

53分钟前

磁谷科技股东宝利丰拟减持,不超过总股本3%

6月29日,磁谷科技公告显示,股东南京宝利丰创业投资合伙企业(有限合伙)因自身资金安排,拟通过集中竞价、大宗交易的方式减持其持有的公司股份不超过2,149,569股。减持不超过公司总股本的3.00%。

53分钟前

中信证券:中报季还是以结构性机会为主,预计AI和军工是三季度寻找结构性机会的重心

近日,中信证券研报指出,从板块轮动来看,活跃资金或正从医药和消费切向科技和金融,红利也开始滞涨。结构性机会仍料将是贯穿中报季的话题,指数型机会可能还需要等三季度末到四季度。预计AI和军工是三季度寻找结构性机会的重心。(财联社)

53分钟前

*ST金刚:孙公司金刚数智签订3.99亿元重大算力销售合同

6月29日,*ST金刚发布公告称,公司下属孙公司北京金刚数海智算科技有限公司(简称“金刚数智”)于2025年6月27日与江苏***大数据有限公司(简称“算力客户”)签订了《智算中心多元算力服务项目之服务协议》。由金刚数智向算力客户提供算力服务,合同含税总金额3.99亿元,服务期限5年,按月度支付算力服务费用。

53分钟前

紫光国微:6月27日以4961.73万元回购77.55万股公司股份

6月29日,紫光国微发布公告称,6月27日公司通过股份回购专用证券账户以集中竞价交易方式实施了首次回购(以下简称“本次回购”)。回购公司股份数量77.55万股,约占公司目前总股本的0.09%,最高成交价为64.28元/股,最低成交价为63.67元/股,成交金额为4961.73万元(不含交易费用)。本次回购资金来源为公司自有资金,回购价格未超过前述回购公司股份方案的规定。

53分钟前

本页详细列出关于SHINVA新华的品牌信息,含品牌所属公司介绍,SHINVA新华所处行业的品牌地位及优势。
咨询